2016-03-15T00:00:00.000-04:00
shareholders,0.778755
Goldman Sachs,-0.443801
client Anthem,-0.310535
Hold,-0.368675
attractive entry point,-0.454283
specialty pharmaceutical company,-0.538885
price target,-0.460375
concerns,-0.19895
Express Scripts shares,-0.454283
consumer health business,-0.538885
recent selloff,-0.438549
favorable risk/reward,0.802623
analyst Jami Rubin,-0.455974
kidney transplant revenues,-0.356101
analyst Heath Terry,-0.431628
long-term organic growth,0.420429
Street Research coverage,0.331803
free cash flow,0.414943
differentiated profile,-0.356307
enterprise value,0.802623
analyst George Hill,-0.258051
analyst coverage,0.701499
analyst Yigal Nochomovitz,-0.365516
Q4 earnings,-0.392685
Fly,0.516651
attractive acquisition target,0.802623
capital return,0.778755
Deutsche Bank analyst,-0.216948
Instant Booking,0.230706
contract linger,-0.392685
Express Scripts,-0.304506
preferred means,0.778755
downside potential,-0.681676
significant negative earnings,-0.438411
share repurchases,0.778755
negative earnings revision,-0.438411
Conviction Buy,-0.431628
